A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Active, not recruiting · NCT03611868 · Registry updated 2025-08-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, connective tissue neoplasm, cutaneous melanoma, eye disorder, fibrosarcoma, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroendocrine neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, sarcoma, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Active, not recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT03611868 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ascentage Pharma Group Inc. | 30 |
| Merck Sharp & Dohme LLC | 650 |
21 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.